What are the most important unanswered research questions in trial retention? A James Lind Alliance Priority Setting Partnership: the PRioRiTy II (Prioritising Retention in Randomised Trials) study.
James Lind Alliance
Participant retention
Participation in randomised trials
Patient and public involvement
Priority Setting Partnership
Retention challenges
Trials methodology
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
15 Oct 2019
15 Oct 2019
Historique:
received:
20
02
2019
accepted:
29
08
2019
entrez:
17
10
2019
pubmed:
17
10
2019
medline:
16
4
2020
Statut:
epublish
Résumé
One of the top three research priorities for the UK clinical trial community is to address the gap in evidence-based approaches to improving participant retention in randomised trials. Despite this, there is little evidence supporting methods to improve retention. This paper reports the PRioRiTy II project, a Priority Setting Partnership (PSP) that identified and prioritised unanswered questions and uncertainties around trial retention in collaboration with key stakeholders. This PSP was conducted in collaboration with the James Lind Alliance, a non-profit making initiative, to support key stakeholders (researchers, patients, and the public) in jointly identifying and agreeing on priority research questions. There were three stages. (1) First an initial online survey was conducted consisting of six open-ended questions about retention in randomised trials. Responses were coded into thematic groups to create a longlist of questions. The longlist of questions was checked against existing evidence to ensure that they had not been answered by existing research. (2) An interim stage involved a further online survey where stakeholders were asked to select questions of key importance from the longlist. (3) A face-to-face consensus meeting was held, where key stakeholder representatives agreed on an ordered list of 21 unanswered research questions for methods of improving retention in randomised trials. A total of 456 respondents yielded 2431 answers to six open-ended questions, from which 372 questions specifically about retention were identified. Further analysis included thematically grouping all data items within answers and merging questions in consultation with the Steering Group. This produced 27 questions for further rating during the interim survey. The top 21 questions from the interim online survey were brought to a face-to-face consensus meeting in which key stakeholder representatives prioritised the order. The 'Top 10' of these are reported in this paper. The number one ranked question was 'What motivates a participant's decision to complete a clinical trial?' The entire list will be available at www.priorityresearch.ie . The Top 10 list can inform the direction of future research on trial methods and be used by funders to guide projects aiming to address and improve retention in randomised trials.
Sections du résumé
BACKGROUND
BACKGROUND
One of the top three research priorities for the UK clinical trial community is to address the gap in evidence-based approaches to improving participant retention in randomised trials. Despite this, there is little evidence supporting methods to improve retention. This paper reports the PRioRiTy II project, a Priority Setting Partnership (PSP) that identified and prioritised unanswered questions and uncertainties around trial retention in collaboration with key stakeholders.
METHODS
METHODS
This PSP was conducted in collaboration with the James Lind Alliance, a non-profit making initiative, to support key stakeholders (researchers, patients, and the public) in jointly identifying and agreeing on priority research questions. There were three stages. (1) First an initial online survey was conducted consisting of six open-ended questions about retention in randomised trials. Responses were coded into thematic groups to create a longlist of questions. The longlist of questions was checked against existing evidence to ensure that they had not been answered by existing research. (2) An interim stage involved a further online survey where stakeholders were asked to select questions of key importance from the longlist. (3) A face-to-face consensus meeting was held, where key stakeholder representatives agreed on an ordered list of 21 unanswered research questions for methods of improving retention in randomised trials.
RESULTS
RESULTS
A total of 456 respondents yielded 2431 answers to six open-ended questions, from which 372 questions specifically about retention were identified. Further analysis included thematically grouping all data items within answers and merging questions in consultation with the Steering Group. This produced 27 questions for further rating during the interim survey. The top 21 questions from the interim online survey were brought to a face-to-face consensus meeting in which key stakeholder representatives prioritised the order. The 'Top 10' of these are reported in this paper. The number one ranked question was 'What motivates a participant's decision to complete a clinical trial?' The entire list will be available at www.priorityresearch.ie .
CONCLUSION
CONCLUSIONS
The Top 10 list can inform the direction of future research on trial methods and be used by funders to guide projects aiming to address and improve retention in randomised trials.
Identifiants
pubmed: 31615577
doi: 10.1186/s13063-019-3687-7
pii: 10.1186/s13063-019-3687-7
pmc: PMC6794792
doi:
Types de publication
Consensus Development Conference
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
593Subventions
Organisme : Medical Research Council Methodology Fellowship
ID : MR/L01193X/1
Organisme : Scottish Government Health and Social Care Directorate
ID : CGA/17/49
Organisme : Medical Research Council
ID : MR/L01193X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K024310/1
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : HSRU1
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : CGA/17/49
Pays : United Kingdom
Références
Int J Health Care Qual Assur. 2015;28(2):141-55
pubmed: 26335167
BMJ Open. 2014 Jan 24;4(1):e003835
pubmed: 24464427
Lancet. 2014 Jan 11;383(9912):156-65
pubmed: 24411644
Trials. 2014 Jan 23;15:32
pubmed: 24456928
Lancet. 2014 Jun 14;383(9934):2041-2042
pubmed: 24931684
J Clin Epidemiol. 2017 Aug;88:122-132
pubmed: 28546093
Trials. 2017 Aug 31;18(1):406
pubmed: 28859674
BMJ Open. 2019 Jun 3;9(6):e021959
pubmed: 31164359
Clin Trials. 2015 Oct;12(5):537-9
pubmed: 26253052
Cochrane Database Syst Rev. 2013 Dec 03;(12):MR000032
pubmed: 24297482
BMJ Open. 2014 Dec 04;4(12):e006400
pubmed: 25475243
Dental Press J Orthod. 2022 Jul 04;27(3):e2220290
pubmed: 35792787
Syst Rev. 2018 Feb 20;7(1):30
pubmed: 29458415
Trials. 2013 Jul 17;14:219
pubmed: 23866730
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
Br J Dermatol. 2013 Mar;168(3):577-82
pubmed: 22963149
Trials. 2018 Mar 27;19(1):197
pubmed: 29580260
Trials. 2018 Mar 1;19(1):147
pubmed: 29490702